These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38166793)

  • 21. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug resistance pattern in Mycobacterium tuberculosis to the first line drugs of pulmonary tuberculosis patients at Hazara Region, Pakistan.
    Jan F; Wali S; Sadia S; Akbar MT; Akbar HS; Ahmad W; Ahmad M; Khalid A
    Tuberk Toraks; 2018 Mar; 66(1):26-31. PubMed ID: 30020038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and Drug Resistance Pattern of
    Mohammed KAS; Khudhair GS; Al-Rabeai DB
    Pol J Microbiol; 2022 May; 71(2):205-215. PubMed ID: 35675816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.
    Ambreen A; Jamil M; Rahman MAU; Mustafa T
    BMC Infect Dis; 2019 Oct; 19(1):923. PubMed ID: 31666021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia.
    Tilahun M; Ameni G; Desta K; Zewude A; Yamuah L; Abebe M; Aseffa A
    PLoS One; 2018; 13(2):e0193083. PubMed ID: 29447273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children.
    Garcia-Prats AJ; du Plessis L; Draper HR; Burger A; Seddon JA; Zimri K; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1469-1476. PubMed ID: 27776587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of Mycobacterium tuberculosis Complex Strains Isolated from the Samples of Patients Living in Northern Syria].
    Gazel D; Çeylan K; Çalışkantürk G; Karslıgil T
    Mikrobiyol Bul; 2023 Jul; 57(3):444-453. PubMed ID: 37462307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru.
    Villegas L; Otero L; Sterling TR; Huaman MA; Van der Stuyft P; Gotuzzo E; Seas C
    PLoS One; 2016; 11(4):e0152933. PubMed ID: 27045684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
    Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
    BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes.
    Kritski AL; Rodrigues de Jesus LS; Andrade MK; Werneck-Barroso E; Vieira MA; Haffner A; Riley LW
    Chest; 1997 May; 111(5):1162-7. PubMed ID: 9149564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.